<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04818944</url>
  </required_header>
  <id_info>
    <org_study_id>202010341</org_study_id>
    <nct_id>NCT04818944</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Safety of Continuous IV Tirofiban in Acute Ischemic Stroke</brief_title>
  <acronym>iTREMT</acronym>
  <official_title>A Pilot, Exploratory Clinical Trial to Evaluate the Safety of Using Continuous IV Infusion of Tirofiban (24 Hours) Including Its Efficacy in Improving Perfusion Post Mechanical Thrombectomy in Acute Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will recruit men and non-pregnant women of any ethnic background between the age ≥ 18 and&#xD;
      ≤ 90 years that have acute ischemic stroke and underwent Mechanical Thrombectomy (MT) with&#xD;
      TICI 2b or 2b following MT. These subject's will be will be randomized to placebo vs.&#xD;
      Tirofiban after consent is obtained. This will be administered via continuous IV starting&#xD;
      within 60 minutes of MT procedure completion. At the end of the 24 hour continuous IV dosing&#xD;
      period a CT angiography and CT perfusion (CTA/CTP) will be obtained. The rest of the subjects&#xD;
      inpatient hospital stay will be done per standard of care. The subject's NIHSS and modified&#xD;
      Rankin Score (mRS) will be assessed at 90 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Procedures:&#xD;
&#xD;
        1. Potential subject present with acute ischemic changes to our Emergency department (ED)&#xD;
           and evaluated by stroke neurologist.&#xD;
&#xD;
        2. If the potential subject is a candidate for MT then the patient will be screened for&#xD;
           inclusions / exclusions criteria.&#xD;
&#xD;
        3. Patient will undergo MT per standard of care (SOC).&#xD;
&#xD;
        4. At the end of the procedure, the interventionist will assign a specific score for&#xD;
           reperfusion following MT.&#xD;
&#xD;
        5. If the interventionist assign a score of TICI 2b, then the potential subject will be&#xD;
           eligible to be randomized if she/he meets all the other inclusion /exclusion criteria.&#xD;
&#xD;
        6. If the potential subject has score of TICI 2b after MT and meets all the other&#xD;
           inclusion/exclusion criteria, then the power of attorney( POA) /LAR of the potential&#xD;
           subject will be approached and informed about the study.&#xD;
&#xD;
        7. If the POA /LAR signs the informed consent, then the subject will be randomized to&#xD;
           placebo vs. Tirofiban.&#xD;
&#xD;
        8. The randomization will be 1:1 and will be done by the Investigational Drug Service (IDS)&#xD;
           pharmacy.&#xD;
&#xD;
        9. The informed consent must be signed within 60 min from the end of the MT.&#xD;
&#xD;
       10. If the informed consent is obtained, then the agent (placebo or Tirofiban) will must&#xD;
           initiated no later than 60 min from the end of the MT.&#xD;
&#xD;
       11. The subject will be transferred to SNICU per SOC.&#xD;
&#xD;
       12. The infusion will continue for 24 hours then stopped.&#xD;
&#xD;
       13. At the end of the 24 hours of infusion a CTA/CTP will be obtained to assess perfusion.&#xD;
&#xD;
       14. If the subject neurological exam deteriorates / worsen during the infusion, the&#xD;
           medication will be stopped and unblinded. Non contrast HCT will be obtained immediately&#xD;
           to assess if there is a new hemorrhage.&#xD;
&#xD;
       15. If there is hemorrhage and the subject was on Tirofiban then a pack of platelet will be&#xD;
           ordered infused immediately. If the subject is on placebo, then no need to infuse a pack&#xD;
           of platelets.&#xD;
&#xD;
       16. Platelet count will be assess daily for 48 hours from initiating the medication&#xD;
&#xD;
       17. If the platelet count drops below 20,000, then the medication will be stopped&#xD;
           immediately and unblinded.&#xD;
&#xD;
       18. Th rest of the hospitalization will be done per SOC.&#xD;
&#xD;
       19. The subject's NIHSS and mRS will be assessed at 90 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>All study staff is masked to randomization except the following: nursing staff administrating drug, pharmacy staff, statistician, and independent safety assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Intracranial Hemorrhage</measure>
    <time_frame>Up to 2 weeks post enrollment</time_frame>
    <description>Incidence of intracranial hemorrhage</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Infract Size</measure>
    <time_frame>Up to 2 weeks post enrollment</time_frame>
    <description>Infract size as calculated through imaging methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score</measure>
    <time_frame>90 Day post- discharge follow up</time_frame>
    <description>mRS at clinically indicated follow-up visit. Relative frequency of &quot;good outcome&quot; as defined by dichotomized mRS score 0-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIH Stroke Scale</measure>
    <time_frame>90 Day post- discharge follow up</time_frame>
    <description>NIHSS at clinically indicated follow-up visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive an active dose via continuous IV at a rate of 0.10µg/kg/min (actual weight). This rate will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo (saline) via continuous IV. This will begin within one hour of mechanical thrombectomy completion and will be terminated 24 hours after the initial administration time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tirofiban Hydrochloride</intervention_name>
    <description>Tirofiban Hydrochloride will be dosed for 24 hours post MT via continuous IV</description>
    <arm_group_label>Treatment Arm (tirofiban hydrochloride (AGGRASTAT®))</arm_group_label>
    <other_name>Aggrastat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline will be dosed for 24 hours post MT via continuous IV</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 and ≤ 90 years&#xD;
&#xD;
          -  Acute ischemic stroke (AIS)&#xD;
&#xD;
          -  Onset of AIS 6-24 hrs.&#xD;
&#xD;
          -  NIHSS score ≥ 6&#xD;
&#xD;
          -  AIS due to LVO&#xD;
&#xD;
          -  core infarct &lt;30cc or ASPECT score &gt; 6.&#xD;
&#xD;
          -  Received MT per SOC&#xD;
&#xD;
          -  TICI score of 2B, or TC post MT.&#xD;
&#xD;
          -  Able to be imaged by MRI&#xD;
&#xD;
          -  Patient or their Legally Authorized Representative (LAR) has provided written informed&#xD;
             consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy or hypersensitivity to tirofiban&#xD;
&#xD;
          -  Previous stroke in the past 90 days&#xD;
&#xD;
          -  Previous intracranial hemorrhage, neoplasm, subarachnoid hemorrhage, or arterial&#xD;
             venous malformation&#xD;
&#xD;
          -  Clinical presentation suggested a subarachnoid hemorrhage, even if initial CT scan was&#xD;
             normal&#xD;
&#xD;
          -  Surgery or biopsy of parenchymal organ in the past 30 days&#xD;
&#xD;
          -  Trauma with internal injuries or ulcerative wounds in the past 30 days&#xD;
&#xD;
          -  Severe head trauma in the past 90 days&#xD;
&#xD;
          -  Systolic blood pressure persistently &gt;180mmHg post-MT despite antihypertensive&#xD;
             intervention.&#xD;
&#xD;
          -  Diastolic blood pressure persistently &gt;105mmHg post-MT despite antihypertensive&#xD;
             intervention.&#xD;
&#xD;
          -  Serious systemic hemorrhage in the past 30 days.&#xD;
&#xD;
          -  Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or&#xD;
             oral anticoagulant therapy with INR &gt;1.5&#xD;
&#xD;
          -  Positive urine pregnancy test for women of childbearing potential&#xD;
&#xD;
          -  Glucose &lt;50 or &gt;400 mg/dl&#xD;
&#xD;
          -  Platelets &lt;100,000/mm3&#xD;
&#xD;
          -  Hematocrit &lt;25 %&#xD;
&#xD;
          -  Elevated PTT above laboratory upper limit of normal&#xD;
&#xD;
          -  Creatinine &gt; 4 mg/dl&#xD;
&#xD;
          -  Ongoing renal dialysis, regardless of creatinine&#xD;
&#xD;
          -  Received Low Molecular Weight heparins (such as Dalteparin, Enoxaparin, Tinzaparin) in&#xD;
             full dose within the previous 24 hours&#xD;
&#xD;
          -  Abnormal PTT within 48 hours prior to randomization after receiving heparin or a&#xD;
             direct thrombin inhibitor (such as bivalirudin, argatroban, dabigatran or lepirudin)&#xD;
&#xD;
          -  Received Factor Xa inhibitors (such as Fondaparinux, apixaban or rivaroxaban) within&#xD;
             the past 48 hours&#xD;
&#xD;
          -  Received iv tPA&#xD;
&#xD;
          -  Pre-existing neurological or psychiatric disease which confounded the neurological or&#xD;
             functional evaluations e.g., baseline modified Rankin score &gt;3&#xD;
&#xD;
          -  Other serious, advanced, or terminal illness or any other condition that the&#xD;
             investigator felt would pose a significant hazard to the patient if tirofiban therapy&#xD;
             was initiated a. Example: known cirrhosis or clinically significant hepatic disease&#xD;
&#xD;
          -  Current participation in another research drug treatment or interventional device&#xD;
             trial&#xD;
&#xD;
          -  Informed consent from the patient or the legally authorized representative was not or&#xD;
             could not be obtained&#xD;
&#xD;
          -  High density lesion consistent with hemorrhage of any degree&#xD;
&#xD;
          -  ASPECT score &lt; 6&#xD;
&#xD;
          -  Deployment of a stent INTRA and/or EXTRA-cranial&#xD;
&#xD;
          -  Did not receive MT&#xD;
&#xD;
          -  TICI score of 3 post MT&#xD;
&#xD;
          -  Extravasation of contrast during procedure&#xD;
&#xD;
          -  Perforation of any vessel during procedure.&#xD;
&#xD;
          -  Renal dysfunction&#xD;
&#xD;
          -  History of gastrointestinal hemorrhage or major systemic hemorrhage within 30 days,&#xD;
             hemoglobin less than 8 g/dL on admission, INR ≥1.5, severe liver impairment as defined&#xD;
             as AST, ALT, AP, GGT &gt; 2 x normal&#xD;
&#xD;
          -  Creatinine clearance &lt;30 mL/min.&#xD;
&#xD;
          -  Major surgery within 30 days with contra-indication to antiplatelet therapy&#xD;
&#xD;
          -  Currently pregnant.&#xD;
&#xD;
          -  Contraindication for MRI&#xD;
&#xD;
          -  Contra-indication to antiplatelet tirofiban:&#xD;
&#xD;
               1. Active internal bleeding or a history of bleeding diathesis within the previous&#xD;
                  30 days&#xD;
&#xD;
               2. History of thrombocytopenia following prior exposure to AGGRASTAT&#xD;
&#xD;
               3. History, symptoms, or findings suggestive of aortic dissection&#xD;
&#xD;
               4. Acute pericarditis&#xD;
&#xD;
          -  Actual Body Weight &gt;150kg (due to the lack of safety data)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Hasan, MD, MS</last_name>
    <phone>(319) 384-8669</phone>
    <email>david-hasan@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eleanor Ryan</last_name>
    <phone>(319) 467-4677</phone>
    <email>eleanor-ryan@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 26, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>David Hasan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mechanical Thrombectomy</keyword>
  <keyword>Tirofiban</keyword>
  <keyword>Distal Vessel Reperfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tirofiban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

